317 related articles for article (PubMed ID: 31118938)
1. Dopamine Receptor D3 Expression Is Altered in CD4
Elgueta D; Contreras F; Prado C; Montoya A; Ugalde V; Chovar O; Villagra R; Henríquez C; Abellanas MA; Aymerich MS; Franco R; Pacheco R
Front Immunol; 2019; 10():981. PubMed ID: 31118938
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
Elgueta D; Aymerich MS; Contreras F; Montoya A; Celorrio M; Rojo-Bustamante E; Riquelme E; González H; Vásquez M; Franco R; Pacheco R
Neuropharmacology; 2017 Feb; 113(Pt A):110-123. PubMed ID: 27693549
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
4. Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation.
Montoya A; Elgueta D; Campos J; Chovar O; Falcón P; Matus S; Alfaro I; Bono MR; Pacheco R
J Neuroinflammation; 2019 Dec; 16(1):258. PubMed ID: 31810491
[TBL] [Abstract][Full Text] [Related]
5. Dopamine Receptor D3 Signaling on CD4+ T Cells Favors Th1- and Th17-Mediated Immunity.
Contreras F; Prado C; González H; Franz D; Osorio-Barrios F; Osorio F; Ugalde V; Lopez E; Elgueta D; Figueroa A; Lladser A; Pacheco R
J Immunol; 2016 May; 196(10):4143-9. PubMed ID: 27183640
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor D2 on CD4
Liu Z; Zhai XR; Du ZS; Xu FF; Huang Y; Wang XQ; Qiu YH; Peng YP
Brain Behav Immun; 2021 Nov; 98():110-121. PubMed ID: 34403737
[TBL] [Abstract][Full Text] [Related]
7. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
8. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
[TBL] [Abstract][Full Text] [Related]
9. Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.
Cote SR; Kuzhikandathil EV
Neurosci Lett; 2015 Jan; 585():33-7. PubMed ID: 25445374
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients.
Kustrimovic N; Comi C; Magistrelli L; Rasini E; Legnaro M; Bombelli R; Aleksic I; Blandini F; Minafra B; Riboldazzi G; Sturchio A; Mauri M; Bono G; Marino F; Cosentino M
J Neuroinflammation; 2018 Jul; 15(1):205. PubMed ID: 30001736
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells.
González H; Contreras F; Pacheco R
J Neuroimmune Pharmacol; 2015 Dec; 10(4):561-75. PubMed ID: 26018603
[TBL] [Abstract][Full Text] [Related]
13. Hydroxysafflor Yellow A Improves Motor Dysfunction in the Rotenone-Induced Mice Model of Parkinson's Disease.
Wang T; Wang L; Li C; Han B; Wang Z; Li J; Lv Y; Wang S; Fu F
Neurochem Res; 2017 May; 42(5):1325-1332. PubMed ID: 28097465
[TBL] [Abstract][Full Text] [Related]
14. A dysfunction of CD4+ T lymphocytes in peripheral immune system of Parkinson's disease model mice.
Huang Y; Liu Z; Wang XQ; Qiu YH; Peng YP
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Nov; 30(6):567-76. PubMed ID: 26016368
[TBL] [Abstract][Full Text] [Related]
15. The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease.
Rabaneda-Lombarte N; Serratosa J; Bové J; Vila M; Saura J; Solà C
J Neuroinflammation; 2021 Apr; 18(1):88. PubMed ID: 33823877
[TBL] [Abstract][Full Text] [Related]
16. Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease.
Tassan Mazzocco M; Serra M; Maspero M; Coliva A; Presotto L; Casu MA; Morelli M; Moresco RM; Belloli S; Pinna A
Exp Neurol; 2024 Apr; 374():114704. PubMed ID: 38281587
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity.
Prado C; Osorio-Barrios F; Falcón P; Espinoza A; Saez JJ; Yuseff MI; Pacheco R
J Neuroinflammation; 2021 Dec; 18(1):292. PubMed ID: 34920747
[TBL] [Abstract][Full Text] [Related]
18. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
19. Defining the contribution of neuroinflammation to Parkinson's disease in humanized immune system mice.
Manocha GD; Floden AM; Puig KL; Nagamoto-Combs K; Scherzer CR; Combs CK
Mol Neurodegener; 2017 Feb; 12(1):17. PubMed ID: 28196514
[TBL] [Abstract][Full Text] [Related]
20. Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model.
Zhang Y; Qin L; Xie J; Li J; Wang C
Life Sci; 2020 Jul; 253():117745. PubMed ID: 32376269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
